Open AccessImpact of Inhaled and Intranasal Corticosteroids Exposure on the Risk of Ocular Hypertension and Glaucoma: A Systematic Review and Meta-Analysis
Author(s) -
Anastasiya Vinokurtseva,
Matthew Fung,
Erica Ai Li,
Richard Zhang,
James J. Armstrong,
Cindy Hutnik
Publication year - 2022
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s358066
Subject(s) - medicine , glaucoma , ocular hypertension , intraocular pressure , incidence (geometry) , meta analysis , cinahl , population , ophthalmology , systematic review , medline , physics , environmental health , psychiatry , political science , psychological intervention , law , optics
Starting in 2019, the Global Initiative for Asthma recommended the use of inhaled corticosteroids (ICS) as part of reliever combination therapy in patients 12 years of age and older, thus dramatically increasing the population exposure to ICS. ICS and intranasal corticosteroids (INS) are commonly used for a variety of respiratory diseases. Chronic steroid use is a well-known risk factor for elevated intraocular pressure (IOP) and glaucoma regardless of route of administration. This study aimed to determine the reported risk of glaucoma, ocular hypertension (OHT) and IOP elevation associated with ICS and INS use.